SFM
COGT icon

Sphera Funds Management’s Cogent Biosciences COGT Stock Holding History

Sphera Funds Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-200,000
Closed -$1.44M – 118
2025
Q2 		$1.44M Buy
+200,000
New +$1.11M 0.34% 76

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Sphera Funds Management's COGT Position: Q1 2026 in Review

Sphera Funds Management increased its Cogent Biosciences (COGT) stake by 10% in Q1 2026, buying an estimated $1.4M and bringing the position to 416,340 shares worth $16M. The position accounts for 2.54% of the portfolio, ranked #11.

Sphera Funds Management first reported a position in COGT in Q4 2020 and has held it in 11 quarters since. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Sphera Funds Management held 416,340 shares of Cogent Biosciences worth $16M as of Q1 2026.
  • Sphera Funds Management bought 37,840 Cogent Biosciences shares in Q1 2026, an estimated $1.4M.
  • Cogent Biosciences made up 2.54% of Sphera Funds Management's portfolio in Q1 2026, its #11 holding.
  • Sphera Funds Management first reported a position in Cogent Biosciences in Q4 2020 and has held it in 11 quarters since.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Sphera Funds Management's 13F filing for Q1 2026, filed 15 May 2026.